ArticleClinical & translational immunology2026
A novel surface plasmon resonance approach to assess anti-dsDNA antibody kinetics and disease severity in systemic lupus erythematosus.
Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Anti-dsDNA antibodies are established biomarkers in systemic lupus erythematosus (SLE), yet the clinical utility of conventional assays remains limited by variable analytical performance. We evaluated a novel Fibre-Optic Surface Plasmon Resonance (FO-SPR) biosensor for real-time profiling of anti-dsDNA antibody-antigen interactions and investigated whether kinetic parameters are associated with disease severity, particularly lupus nephritis (LN). Methods: Sera from 26 SLE patients (including 12 with LN), 14 disease controls and 16 healthy donors were analysed using FO-SPR biosensors coated with biotinylated dsDNA. The sensors generated real-time kinetic profiles from which maximum binding response ( Results: The FO-SPR platform enabled reliable detection of anti-dsDNA antibodies and clearly distinguished SLE patients with renal involvement: Eight of 12 LN patients showed Conclusion: This study highlights the value of an innovative FO-SPR biosensor for real-time characterisation of anti-dsDNA antibody affinity. The kinetic profiles captured by this platform provide clinically relevant insights, particularly for distinguishing LN patients from other SLE phenotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.